Ärztliche Mitarbeiter

• 1996-2003
  Medical school, (Final grade: Sehr gut, highest honors), University of Hamburg, Germany; Humboldt University, Berlin, Germany; University  of Freiburg, Germany.

• 1999-2003
  MD thesis, Department of Internal Medicine, Division 4, University of Freiburg. Entitled: Expression of functional CC- and CXC chemokine receptors in podocytes. Advisor: Prof. Dr. H. Pavenstädt (Grade: Summa cum laude, highest honors)

• since 2020
  Professor for Hematology and Stem Cell Transplantation (W3), University Hospital Essen

• since 2020
  Director Clinic for Hematology and Stem Cell Transplantation,University Hospital Essen

• since 2020
  Elected member of the board of the Competence Network Malignant Lymphoma

• since 2019
  Elected Vice-Speaker of the network of Mildred Scheel Schools of Oncology  (Hamburg, Würzburg, Dresden, Frankfurt, Köln-Bonn)

• since 2019
  Co-Speaker Collaborative Research Center „Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer“ (SFB-1399)

• since 2018
  Speaker of the Mildred Scheel School of Oncology Cologne-Bonn: Cancer- and  Immuno-genomics

• since 2017
  Speaker of the Else Kröner Research College: Clonal evolution in cancer

• 2015-2020
  Attending physician at the Medical Clinic I of the University Hospital Cologne

• 2015
  Board exam (certified in general internal medicine and hematology and medical  oncology)

• 2015-2020
  Elected member of the executive board of the Center for Molecular Medicine Cologne

• 2013-2019
  Head of the Clinical Research Unit-286 “Exploiting defects in the DNA damage response for the treatment of chronic lymphocytic leukemia”

• 2012-2015
  Elected member of the steering committee of the Helmholtz Alliance Preclinical Comprehensive Cancer Center (PCCC) and scientific coordinator of Research Topic 3, Hematological Malignancies within the PCCC

• 2012-2020
  Professor for Clinical and Molecular Oncology (W2), University Hospital Cologne

• 2009-2015
  Emmy-Noether research group leader at the Max-Planck-Institute Cologne and the Medical Clinic I of the University Hospital Cologne

• 2009
  Habilitation for Molecular Medicine at the Medical Faculty of the University of Cologne

• 2004-2009
  Postdoctoral Associate, MIT, Department of Biology, Koch Institute, Advisors: Profs. M.B. Yaffe, MD, PhD and T. Jacks, PhD

• 2004
  Postdoctoral Research Fellow, University of Münster, Germany, Advisor: Prof. Dr. H. Pavenstädt.

• 2003
  Postdoctoral Research Fellow University of Freiburg, Germany,Advisor: Profs. Dr. G. Walz and Dr. T. Benzing

2017:  Gilead Research Award Oncology

2016:  Theodor Frerichs Award of the German Society for Internal Medicine

2012:  GlaxoSmithKline Research Award

2011:  Vincenz Czerny Award of the German Society for Hematology and Oncology

2011:  W2 Lichtenberg Professorship of the VolkswagenStiftung

2011:  CESAR Research Award of the Central European Society for Anticancer Drug Research

2011:  Johann-Georg-Zimmermann Award for Cancer Research

2010:  Young Leaders in Science Award of the Schering Stiftung

2009:  Emmy-Noether fellowship of the Deutsche Forschungsgemeinschaft

2009:  Startup grant from the Ministerium für Innovation, Wissenschaft, Forschung und Technologie des Landes NRW

2009:  NIH/NCI K99/R00 PI award (relinquished due to return to Germany)

2009:  Travel grant of the Deutsche Krebshilfe

2007:  MIT-Koch Award

2005:  Research fellowship of the Deutsche Forschungsgemeinschaft

2004:  Young investigator award of the Deutsche Nierenstiftung

1. Deutsche Gesellschaft für Innere Medizin
2. Deutsche Gesellschaft für Hämatologie und Onkologie
3. Deutsche Krebsgesellschaft
4. Deutsche Gesellschaft für DNA Reparaturforschung
5. Deutscher Hochschulverband
6. Kompetenznetz Maligne Lymphome
7. German Lymphoma Alliance
8. European Hematology Association
9. American Association for Cancer Research
10. European Association for Cancer Research
11. European Society of Medical Oncology
12. Central European Society for Anticancer Drug Research
13. Gesellschaft für Versuchstierkunde / Society of Laboratory Animal Science (GV-SOLAS)
14. Verband der Leitenden Krankenhausärzte

1. Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun A, Ozretić L, Künstlinger H, Kambartel   K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC: A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell, 2015 Jul 2;162(1):146-59.
   
   
2. Jachimowicz RD, Beleggia F, Isensee J, Bhavana VB, Goergens J, Bustos MA, Doll MA, Shenoy A, Checa-Rodriguez C, Wiederstein JL, Baranes-Bachar K, Bartenhagen C, Hertwig    F, Teper N, Nishi T, Schmitt A, Distelmaier F, Lüdecke HJ, Albrecht B, Krüger M, Schumacher  B, Geiger T, Hoon DSB, Huertas P, Fischer M, Hucho T, Peifer M, Ziv Y, Reinhardt HC*#, Wieczorek D*, Shiloh Y*: UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors, Cell, 2019 Jan 24;176(3):505-519.e22, * Shared last   authors, # lead author contact
   
   
3. Janes KA*, Reinhardt HC*, and Yaffe MB: Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell, 2008 Oct 17;135(2):343-54. *equal contribution
   
   
4. Reinhardt HC, Aslanian AS, Lees JA, and Yaffe MB: p53 deficient cells rely on ATM and ATR-mediated checkpoint signaling through the p38 MAPK/MK2 pathway for survival after DNA damage. Cancer Cell, 2007 Feb;11(2):175-89.
   
   
5. Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, van Oers J, Edelmann W, Heukamp LC, Reinhardt HC: A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discovery, 2014 May;4(5):592-605.
   
   
6. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, Leenders F, Lu X, Fernandez-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan N, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub B, Becker C, Altmüller J, Yokota J, Khono T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Peterson I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion P, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell P, Solomon B, Koch I, Lindner M, Muscarella LA, La Torre A, Field JK, Jakopovic M, Knezevic J, Castanos-Velez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Bolting J, Sandlin M, Sanchez-Cespedes M, Salvesen H, Achter V, Lang U, Bogus M, Schneider P, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt HC, Perner S, Heukamp LC , Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK: Comprehensive genomic profiling of small cell lung cancer. Nature, 2015 Jul 13.
   
   
7. Wilker EW, van Vugt MA, Artim SA, Huang PH, Petersen CP, Reinhardt HC, Feng Y, Sharp PA, Sonenberg N, White FM, Yaffe MB.: 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature. 2007 Mar 15;446(7133)
   
   
8. Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, Thomas RK, Kreuzer KA, Frenzel LP, Monfared P, Martins-Boucas JM, Chen S, Reinhardt HC: Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med, 2013 Jun 12;5(189):189ra78.
   
   
9. Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt M, Wang X, Linding R, Ong SE, Weaver D, Carr SA, Yaffe MB. DNA Damage activates A Spatially Distinct Late Cytoplasmic Cell Cycle Checkpoint Network Controlled by MK2-mediated RNA Stabilization. Mol Cell, 2010, 40;1, 34-49, 2010 Oct 8
   
   
10. Knittel G, Liedgens P, Korovkina D, Seeger JM, Al-Baldawi Y, Al-Maarri M, Fritz C, Vlantis K, Bezhanova S, Scheel AH, Wolz OO, Reimann M, Möller P, López C, Schlesner M, Lohneis P, Weber ANR, Trümper L, ICGC MMML-Seq Consortium, Staudt LM, Ortmann M, Pasparakis M, Siebert R, Schmitt CA, Klatt AR, Wunderlich FT, Schäfer SC, Persigehl T, Montesinos-Rongen M, Odenthal M, Büttner R, Frenzel LP, Kashkar H, Reinhardt HC: B cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B cell lymphoma in mice. Blood, 2016 Jun 2;127(22):2732-41.